148 related articles for article (PubMed ID: 12091352)
21. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases.
Tatton L; Morley GM; Chopra R; Khwaja A
J Biol Chem; 2003 Feb; 278(7):4847-53. PubMed ID: 12475982
[TBL] [Abstract][Full Text] [Related]
22. New approaches to therapy for mastocytosis. A case for treatment with kit kinase inhibitors.
Longley BJ; Ma Y; Carter E; McMahon G
Hematol Oncol Clin North Am; 2000 Jun; 14(3):689-95. PubMed ID: 10909046
[TBL] [Abstract][Full Text] [Related]
23. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
24. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
Frost MJ; Ferrao PT; Hughes TP; Ashman LK
Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
[TBL] [Abstract][Full Text] [Related]
25. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit.
London CA; Galli SJ; Yuuki T; Hu ZQ; Helfand SC; Geissler EN
Exp Hematol; 1999 Apr; 27(4):689-97. PubMed ID: 10210327
[TBL] [Abstract][Full Text] [Related]
26. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
27. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region.
Chan PM; Ilangumaran S; La Rose J; Chakrabartty A; Rottapel R
Mol Cell Biol; 2003 May; 23(9):3067-78. PubMed ID: 12697809
[TBL] [Abstract][Full Text] [Related]
28. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
[TBL] [Abstract][Full Text] [Related]
29. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells.
Piao X; Bernstein A
Blood; 1996 Apr; 87(8):3117-23. PubMed ID: 8605325
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.
Corbin AS; Demehri S; Griswold IJ; Wang Y; Metcalf CA; Sundaramoorthi R; Shakespeare WC; Snodgrass J; Wardwell S; Dalgarno D; Iuliucci J; Sawyer TK; Heinrich MC; Druker BJ; Deininger MW
Blood; 2005 Jul; 106(1):227-34. PubMed ID: 15746079
[TBL] [Abstract][Full Text] [Related]
31. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
[TBL] [Abstract][Full Text] [Related]
32. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
Growney JD; Clark JJ; Adelsperger J; Stone R; Fabbro D; Griffin JD; Gilliland DG
Blood; 2005 Jul; 106(2):721-4. PubMed ID: 15790786
[TBL] [Abstract][Full Text] [Related]
33. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
34. Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930.
Petti F; Thelemann A; Kahler J; McCormack S; Castaldo L; Hunt T; Nuwaysir L; Zeiske L; Haack H; Sullivan L; Garton A; Haley JD
Mol Cancer Ther; 2005 Aug; 4(8):1186-97. PubMed ID: 16093434
[TBL] [Abstract][Full Text] [Related]
35. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
Wisniewski D; Lambek CL; Liu C; Strife A; Veach DR; Nagar B; Young MA; Schindler T; Bornmann WG; Bertino JR; Kuriyan J; Clarkson B
Cancer Res; 2002 Aug; 62(15):4244-55. PubMed ID: 12154026
[TBL] [Abstract][Full Text] [Related]
36. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.
Takeuchi Y; Fujino Y; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
Vet Immunol Immunopathol; 2010 Oct; 137(3-4):208-16. PubMed ID: 20591500
[TBL] [Abstract][Full Text] [Related]
37. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
Ali S; Ali S
Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849
[TBL] [Abstract][Full Text] [Related]
38. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
Jin Y; Ding K; Wang D; Shen M; Pan J
Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
[TBL] [Abstract][Full Text] [Related]
39. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms.
Ma Y; Longley BJ; Wang X; Blount JL; Langley K; Caughey GH
J Invest Dermatol; 1999 Feb; 112(2):165-70. PubMed ID: 9989791
[TBL] [Abstract][Full Text] [Related]
40. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
Dubreuil P; Letard S; Ciufolini M; Gros L; Humbert M; Castéran N; Borge L; Hajem B; Lermet A; Sippl W; Voisset E; Arock M; Auclair C; Leventhal PS; Mansfield CD; Moussy A; Hermine O
PLoS One; 2009 Sep; 4(9):e7258. PubMed ID: 19789626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
